Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

A hypercoagulable and hypofibrinolytic state is detectable by global methods in patients with retinal vein occlusion.

Authors: Cellai, AP  Lami, D  Fedi, S  Marcucci, R  Mannini, L  Cenci, C  Rogolino, A  Sodi, A  Menchini, U  Abbate, R  Prisco, D 
Citation: Cellai AP, etal., Atherosclerosis. 2012 Sep;224(1):97-101. doi: 10.1016/j.atherosclerosis.2012.06.053. Epub 2012 Jul 3.
Pubmed: (View Article at PubMed) PMID:22800650
DOI: Full-text: DOI:10.1016/j.atherosclerosis.2012.06.053

The pathogenesis of retinal vein occlusion (RVO), has not been well understood. Recent data have shown the efficacy of an anticoagulant therapy with LMWHs in the treatment of acute RVO suggesting the presence of a hypercoagulable state in these patients. New global tests for detection of hypercoagulability and hypofibrinolysis have become available and their application might improve the knowledge of the pathophysiology of RVO and, potentially, its treatment. The aim of our study was to evaluate coagulation and fibrinolytic alterations by two global tests in RVO patients: Endogenous Thrombin Potential (ETP) and Clot Lysis Time (CLT), respectively. We studied 81 RVO patients (40 males; median age 61 years) and a control group matched for age and sex. The ETP was measured by functional chromogenic assay and expressed as the time until thrombin burst (LagTime), Time to peak (T(max)), Peak amount of thrombin generation (C(max)) and ETP. CLT was determined by a plasma-based, tissue factor-induced clot lysis assay. C(max), ETP and CLT values were significantly higher in RVO patients than in controls (C(max)p = 0.010; ETP p < 0.001; CLT p < 0.001) and remained significantly associated with the disease at the multivariate analysis adjusted for cardiovascular risk factors. Our results indicate that -beyond the assay of different parameters associated with clotting activation and lysis- global methods might allow us to easily detect the presence of hypercoagulability and hypofibrinolysis in RVO patients. Further studies should assess the possible clinical value of our data in the management of RVO patients.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 7387258
Created: 2013-10-24
Species: All species
Last Modified: 2013-10-24
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.